Peucedanocoumarin III

Peucedanocoumarin III is an inhibitor of (alpha) -synuclein and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein) . Peucedanocoumarin III may be used in Parkinson's disease research[1].

Product Specifications

CAS Number

[130464-57-2]

UNSPSC

12352005

Target

α-synuclein

Type

Natural Products

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/peucedanocoumarin-iii.html

Purity

95.07

Solubility

10 mM in DMSO

Smiles

C/C=C(C)/C(O[C@@H]1C2=C(OC(C)([C@H]1OC(C)=O)C)C=CC(C=C3)=C2OC3=O)=O

Molecular Formula

C21H22O7

Molecular Weight

386.40

References & Citations

[1]Sangwoo Ham, et al. Cell-Based Screen Using Amyloid Mimic β23 Expression Identifies Peucedanocoumarin III as a Novel Inhibitor of α-Synuclein and Huntingtin Aggregates. Mol Cells. 2019 Jun 30;42 (6) :480-494.